In chronic liver disease the disposition and elimination of many lipid soluble drugs are altered.1 2 The hepatic metabolism of these agents may be determined by the capacity of the oxidising and con)ugating enzyme systems and the liver blood flow, both of which may be impaired in the presence of cirrhosis. 4 The pharmacological response to a drug may also be abnormal in liver disease and, in particular, the cerebral sensitivity to sedative drugs may be increased. 5 Patients with chronic liver disease are frequently referred for upper gastrointestinal endoscopy either for the diagnostic assessment of gastrointestinal haemorrhage or dyspepsia or for therapeutic injection sclerotherapy of oesophageal varices.6 Diazepam is commonly used as the premedicating sedative, but in-patients with liver disease the half life of this drug may exceed 100 hours,7 and some patients exhibit increased cerebral sensitivity.8 9 Midazolam is a new benzodiazepine consisting of an imidazole ring fused at the 1-2 position with a diazepine ring. Its hypnotic action is brief and its elimination half life is under four hours and in some patients is as short as two hours.1>-2 These properties make it a potentially useful sedative for minor Address for correspondence: Dr G Birnie, Gardiner Institute, Western Infirmary, Dumbarton Road, Glasgow Gil 6NT.
Received for publication 7 May 1985 invasive procedures. It is metabolised in the liver by hydroxylation and conjugation with glucuronic acid.13 It has a high hepatic extraction ratio10 and so its elimination would be expected to be dependent on liver blood flow.
The aims of this study were to compare the pharmacokinetic profile and pharmacodynamic response after an intravenous dose of midazolam in patients with hepatic cirrhosis and those with normal liver function. Secondly, to assess the value of antipyrine and indocyanine green kinetics in predicting midazolam pharmacokinetics and dynamics.
Methods

PATIENTS
Seven patients with hepatic cirrhosis and eight patient controls agreed to take part in the study. All gave written informed consent to inclusion in the study which was approved by the local hospital ethical committee.
The cirrhotic patients were aged between 39 and 54 years and all had biopsy proven alcoholic cirrhosis. They were referred for endoscopy for the assessment of portal hypertension. Five Statistical analyses were by Mann Whitney U tests and paired Wilcoxon's signed rank tests. The correlation coefficients were calculated using the Spearman ranking procedure.
Results
All patients became overtly sedated as a result of the administration of midazolam and endoscopy was accomplished with minimal difficulty. The standard biochemical liver function tests were all significantly deranged in the cirrhotic patients (Table 1) .
PHARMACOKINETICS
The elimination of antipyrine and indocyanine green in the two groups is shown in Table 2 ; there was a highly significant prolongation of the half lives of both drugs in the cirrhotic patients (p<0001), with Figure 1 ) high plasma concentrations of midazolam were found throughout the duration of the study. If the values are true there the greatly prolonged estimated half life would preclude the calculation of acceptable kinetic parameters. Another possibility is that these results are because of some substance interfering with the assay, but attempts have failed to identify an interfering peak. The analytical data from these patients are therefore plotted separately and are not included in the statistical analysis of the midazolam kinetics. The distribution half life of midazolam was slightly reduced in the cirrhotic patients compared to the controls (cirrhosis=4*58±1*83 mins vs controls=6*44±1-08 min) but this difference did not reach statistical significance. The elimination half lives were significantly prolonged in the cirrhotic group (cirrhosis=2*89±1*08 hours vs controls=1-65±0O26: p<0025) and the clearances were appropriately reduced (cirrhosis=5*67±099 ml/ min/kg vs controls=10-62 ml/min/kg: p<0025).
There were no significant correlations between the clearance of midazolam with the serum albumin, serum bilirubin, or with the clearances or half lives of antipyrine or indocyanine green.
PHARMACODYNAMICS
All the control and cirrhotic patients were included in these analyses.
Choice reaction time
The CRT 1 (recognition time) and CRT 2 Time (h) I impairment in the control patients was a reduced CFFT at one hour. Subjectively they were sedated sufficiently to allow endoscopy to be carried out. Using the recognition time and the total reaction time there was objective evidence of psychomotor impairment in the cirrhotic patients which was significant for up to six hours after the administration of midazolam. The maximum prolongation in CRT occurred in the cirrhotics at two hours (Figs. 2  and 3 ). This occurred when there was a small but significantly higher plasma midazolam than in the control patients. These results could be interpreted to suggest that there may be increased cerebral sensitivity to midazolam in these patients with chronic liver disease.
The results of the critical flicker fusion threshold are difficult to interpret because of the significantly reduced baseline in the cirrhotic patients (this problem has also occurred in a similarly designed study, with another psychoactive agent20). If this apparent initial abnormality represents subclinical portosystemic encephalopathy then the CFFT merits further study as a possible simple means of identifying and monitoring the early stages of this important complication.
The effect of chronic liver disease on the pharmacokinetics and pharmacodynamics of the benzodiazepines varies between the drugs.21 The elimination half life of diazepam is prolonged in cirrhotics, mainly because of a reduction in the volume of distribution.9 Similarly Kraus et a!22 reported a reduced elimination half life of lorazepam attributable to a fall in the volume of distribution. Chlordiazepoxide has a low intrinsic clearance and a high level of protein binding. In cirrhosis both are reduced and the volume of distribution is increased producing a half life which is markedly prolonged. 23 The elimination of oxazepam, a conjugated benzodiazepine, appears to be unaltered in both acute viral hepatitis or in cirrhosis.24 Direct comparisons of midazolam and diazepam in patients without liver disease undergoing diagnostic endoscopy suggest that midazolam produces a more rapid onset of sedation. The degree of sedation is similar and the patient recall is less. 25 26 This study shows a significant delay in the elimination of midazolam and increase in the degree of sedation produced for up to six hours after its administration to patients with severe alcoholic liver disease. Caution should therefore be exercised in administering the drug to patients with chronic liver disease. These changes, however, may be less than those occurring with diazepam and midazolam may prove to be the benzodiazepine of choice in providing premedication for such patients who require to undergo a diagnostic or therapeutic endoscopic procedure. 
